Please note: The information displayed on this page might be outdated.
Oncorus: The leader in next-generation oncolytic immunotherapies. The company's lead program ONCR-177 is a Ph1 oHSV with complementary payloads (PD1, CCL4, IL12, FLT3, CTLA4) to encourage immune stimulation, with readout guided for 2H21. Secondary programs include intravenously delivered synthetic vRNA immunotherapies (CVA21 and SVV) utilizing a novel liquid nanoparticle (LNP) delivery strategy designed to overcome the challenges caused by neutralizing antibodies.
Based in...
US - New England
Clinical Stage
Phase l or ll
Disease Space
Public, USA
Market Cap
50 Hampshire Street
Suite 401
Cambridge, MA 02139
United States

Company Participants at Oncorus Synthetic Day June 2021

  • Ted Ashburn, CEO

Top 10 Holders of Oncorus, Inc.

Institution OS (%) Position Mkt Val ($MM) Source Filing Date
Deerfield Management Company LP 12.17 3,148,977 4.79 13F 3/31/22
MPM Asset Management LLC 11.01 2,849,464 4.33 13F 3/31/22
CHI Advisors LLC 9.34 2,417,436 3.67 13F 3/31/22
Bioimpact Capital LLC 9.18 2,377,031 3.61 13F 3/31/22
Citadel LP 7.30 1,888,469 2.87 13F 3/31/22
Fosun International Ltd. 3.72 962,323 1.46 13F 3/31/22
BlackRock Fund Advisors 3.29 850,783 1.29 13F 3/31/22
Perceptive Advisors LLC 2.91 752,241 1.14 13F 3/31/22
The Vanguard Group, Inc. 2.23 578,420 0.88 Funds 6/30/22
Vanguard Group, Inc. (Subfiler) 2.21 571,708 0.87 13F 3/31/22
Ownership data is sourced through FactSet.

Stock Market Data

Data is being loaded...
Data is being loaded...
Data is being loaded...
Data is being loaded...
Market Data copyright © 2022 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, RTB=Real-Time BATS BZX Price/Quote; not sourced from all markets, RTN=Real-Time NASDAQ Basic+ Price/Quote; not sourced from all markets, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.